Form 4: Nurix Therapeutics Executive Trades Shares

Nurix Therapeutics Chief Legal Officer Christine Ring executed a series of stock transactions on July 2, 2026, under a pre-established Rule 10b5-1 trading plan.

Summary

• Christine Ring, Chief Legal Officer at Nurix Therapeutics, Inc., reported transactions involving common stock and employee stock options on July 2, 2026.
• These transactions were conducted under a Rule 10b5-1 trading plan, designed to comply with affirmative defense conditions for insider trading.
• Ring acquired 5,221 shares of common stock at $1.86 per share and an additional 5,787 shares at $8.72 per share.
• Concurrently, 11,008 shares were disposed of at a weighted average price of $23.56, with individual sale prices ranging from $23.23 to $24.16.
• Following these transactions, Ring beneficially owns 13,579 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While the sale of shares by an executive can be a negative signal, the execution under a pre-arranged Rule 10b5-1 plan mitigates concerns about insider trading and suggests a planned portfolio adjustment rather than a reaction to adverse company news.

Positives

• The transactions were executed under a Rule 10b5-1 plan, indicating adherence to established compliance procedures for insider trading.
• Acquisition of shares at lower price points ($1.86 and $8.72) could be seen as a strategic move by management.
• The weighted average sale price of $23.56 suggests a profitable exit for a portion of the holdings.

Negatives

• A significant number of shares (11,008) were sold, potentially signaling a reduction in the executive's direct stake in the company.
• The sale of shares at prices significantly higher than the acquisition prices, while profitable, reduces the executive's potential upside from future stock appreciation.

Risks

• The sale of a substantial number of shares by a key executive could be interpreted negatively by the market, potentially impacting investor sentiment.
• While executed under a 10b5-1 plan, the timing of sales relative to company performance or upcoming news could still raise scrutiny.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• The transactions were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
• The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Industry Context

StockSavvy.ai notes that Form 4 filings detailing executive stock transactions are common in the biotechnology and pharmaceutical sectors, reflecting the dynamic nature of compensation and executive portfolio management. The use of Rule 10b5-1 plans is a standard practice to ensure compliance with insider trading regulations while allowing executives to diversify or rebalance their holdings.

Stakeholder Impact

• Shareholders: May interpret the sale of shares by an executive as a sign of reduced confidence, although the Rule 10b5-1 plan provides a mitigating factor.
• Employees: The executive's stock transactions do not directly impact employee stock options or benefits but may influence morale depending on market perception.
• Management: Demonstrates adherence to compliance protocols for executive trading.

Next Steps

• The reporting person will continue to hold shares and options as per their vesting schedules and the terms of the Rule 10b5-1 plan.
• Further transactions, if any, will be reported on subsequent Form 4 filings.

Key Dates

Keywords

Form 4, Insider Trading, Rule 10b5-1, Nurix Therapeutics, NRIX, Stock Options, Common Stock, Beneficial Ownership, Christine Ring, SEC Filing